Comparison of CT, PET, and PET/CT for staging of patients with indolent non-hodgkin's lymphoma

Molecular Imaging and Biology

Volumn 11, Issue 4, 2009, Pages 269-274

  Fueger, Barbara J ^a   Yeom, Kristen ^a   Czernin, Johannes ^a   Sayre, James W ^a   Phelps, Michael E ^a   Allen Auerbach, Martin S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Indolent lymphoma; PET; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; FOLLICULAR LYMPHOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGE RECONSTRUCTION; INTERMETHOD COMPARISON; LYMPHOCYTOMA; MALE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NK T CELL LYMPHOMA; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; CONTRAST MEDIA; DATA INTERPRETATION, STATISTICAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMAGE PROCESSING, COMPUTER-ASSISTED; KI-67 ANTIGEN; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 67649400409     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-009-0200-9     Document Type: Article

References (35)

1. Hoh CK, Glaspy J, Rosen P et al (1997) Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 38(3):343-348
2. Jerusalem G, Beguin Y, Fasotte M et al (1999) Whole body positron emission tomograpohy using 18 F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94:429-433
3. Röer W, Hanauske A, Ziegler S et al (1998) Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglucose. Blood 91:4464-4471
4. Buchmann I, Reinhardt M, Elsner K et al (2001) 2-(Fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 91(5):889-899
5. Reinhardt MJ, Herkel C, Altehoefer C, Finke J, Moser E (2005) Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: When do we really need FDG-PET? Ann Oncol 16(9):1524-1529
6. Freudenberg LS, Antoch G, Schutt P et al (2004) FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 31(3):325-329
7. Allen-Auerbach M, Quon A, Weber WA et al (2004) Comparison between 2-deoxy-2-[18F]fluoro-D-Glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. Mol Imaging Biol 6(6):411-416
8. Hernandez-Maraver D, Hernandez-Navarro F, Gomez-Leon N et al (2006) Positron emission tomography/computed tomography: Diagnostic accuracy in lymphoma. Br J Haematol 135(3):293-302
9. Hutchings M, Loft A, Hansen M et al (2006) Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma. Haematologica 91(4):482-489
10. Armitage JO, Weisenburger DD (1998) New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 16(8):2780-2795
11. Tsang RW, Gospodarowicz MK (2005) Radiation therapy for localized low-grade non-Hodgkin's lymphomas. Hematol Oncol 23(1):10-17
12. Karam M, Novak L, Cyriac J, Ali A, Nazeer T, Nugent F (2006) Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer 107(1):175-183
13. Jerusalem G, Beguin Y, Najjar F et al (2001) Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol 12(6):825-830
14. Jerusalem GH, Beguin YP (2002) Positron emission tomography in non-Hodgkin's lymphoma (NHL): Relationship between tracer uptake and pathological findings, including preliminary experience in the staging of low-grade NHL. Clin Lymphoma 3(1):56-61
15. Blum RH, Seymour JF, Wirth A, MacManus M, Hicks RJ (2003) Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma. Clin Lymphoma 4(1):43-49
16. Perry C, Herishanu Y, Metzer U et al (2007) Diagnostic accuracy of PET/ CT in patients with extranodal marginal zone MALT lymphoma. Eur J Haematol 79(3):205-209
17. Schoder H, Noy A, Gonen M et al (2005) Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 23(21):4643-4651
18. Okada J, Yoshikawa K, Itami M et al (1992) Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: A comparison with proliferative activity. J Nuc Med 33:325-329
19. Higashi K, Clavo AC, Wahl RL (1993) Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 34(3):414-419
20. Halpern BS, Dahlbom M, Quon A et al (2004) Impact of patient weight and emission scan duration on PET/CT image quality and lesion detectability. J Nucl Med 45(5):797-801
21. Halpern BS, Dahlbom M, Auerbach MA et al (2005) Optimizing imaging protocols for overweight and obese patients: A lutetium orthosilicate PET/CT study. J Nucl Med 46(4):603-607
22. Goerres GW, Burger C, Schwitter MR, Heidelberg TN, Seifert B, von Schulthess GK (2003) PET/CT of the abdomen: Optimizing the patient breathing pattern. Eur Radiol 13(4):734-739
23. Kinahan PE, Townsend DW, Beyer T, Sashin D (1998) Attenuation correction for a combined 3D PET/CT scanner. Med Phys 25(10):2046-2053
24. Kaplan H, Rosenberg S (1996) The treatment of Hodgkin's disease. Med Clin North Am 50:1591
25. Carbone P, Kaplan H, Musshoff K, Smithers D, Tubiana M (1971) Report of the committee on Hodgkin's disease staging classification. Cancer Res 31:1860-1861
26. Sarantopoulos GP, Gui D, Shintaku P et al (2004) Immunohistochemical analysis of lung carcinomas with pure or partial bronchioloalveolar differentiation. Arch Pathol Lab Med 128(4):406-414
27. Terasaki H, Niki T, Matsuno Y et al (2003) Lung adenocarcinoma with mixed bronchioloalveolar and invasive components: Clinicopathological features, subclassification by extent of invasive foci, and immunohistochemical characterization. Am J Surg Pathol 27(7):937-951
28. Bennett BM (1972) On comparisons of sensitivity, specificity and predictive value of a number of diagnostic procedures. Biometrics 28(3):793-800
29. Najjar F, Hustinx R, Jerusalem G, Fillet G, Rigo P (2001) Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL). Cancer Biother Radiopharm 16(4):297-304
30. Czernin J, Allen-Auerbach M, Schelbert HR (2007) Improvements in cancer staging with PET/CT: Literature-based evidence as of September 2006. J Nucl Med 48(Suppl 1):78S-88S
31. Koster A, Tromp HA, Raemaekers JM et al (2007) The prognostic significance of the intra-follicular tumor cell proliferative rate in follicular lymphoma. Haematologica 92(2):184-190
32. Bodet-Milin C, Kraeber-Bodere F, Moreau P, Campion L, Dupas B, Le Gouill S (2008) Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma. Haematologica 93(3):471-472
33. Hainsworth JD (2003) First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma. Semin Oncol 30(1 Suppl 2):9-15
34. Witzig TE, Vukov AM, Habermann TM et al (2005) Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: A phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 23(6):1103-1108
35. Italiano A, Thyss A (2005) Follicular lymphoma: A therapeutic update. Bull Cancer 92(10):57-64